Top

Journal of Neurology

Published in:

01-09-2014 | Letter to the Editors

Thyroid papillary carcinoma after alemtuzumab therapy for MS

Authors: Richard Ibitoye, Alastair Wilkins

Published in: Journal of Neurology | Issue 9/2014

Excerpt

Dear Sirs, …

Cohen JA et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828CrossRefPubMed

Enewold L et al (2009) Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev 18(3):784–791PubMedCentralCrossRefPubMed

Morris LG et al (2013) The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 23(7):885–891PubMedCentralCrossRefPubMed

Brito JP, Hay ID, Morris JC (2014) Low risk papillary thyroid cancer. BMJ 348:g3045CrossRefPubMed

Title: Thyroid papillary carcinoma after alemtuzumab therapy for MS
Authors: Richard Ibitoye
Alastair Wilkins
Publication date: 01-09-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 9/2014
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-014-7453-1

At a glance: The STEP trials

Springer Medicine

Thyroid papillary carcinoma after alemtuzumab therapy for MS

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2014

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype in a patient with a novel heterozygous POLG mutation

Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia

Smoking and multiple sclerosis: evidence for latitudinal and temporal variation

Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review

Johann Hoffmann (1857–1919)

Screening of mutations in NOL3 in a myoclonic syndromes series